Reference:	FOI.21749.26
Subject:	Breast Cancer
Date of Request:	1 October 2026

Requested:

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
   - Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
   - Abemaciclib + Fulvestrant
   - Alpelisib + Fulvestrant
   - Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only
   - Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel
   - Atezolizumab
   - Capivasertib
   - Capecitabine as a single agent
   - Carboplatin + Paclitaxel
   - Elacestrant
   - Eribulin as a single agent or in combination
   - Everolimus + Exemestane
   - Fulvestrant as a single agent
   - Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
   - Palbociclib + Fulvestrant
   - Parp Inhibitors (Olaparib/Talazoparib)
   - Pembrolizumab Monotherapy
   - Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
   - Carboplatin + Paclitaxel + Pembrolizumab
   - Pertuzumab (Perjeta) + Trastuzumab (Herceptin)
   - Phesgo (Pertuzumab + Trastuzumab in a single injection)
   - Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
   - Ribociclib + Fulvestrant
   - Sacituzumab Govitecan
   - Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
   - Trastuzumab deruxtecan (Enhertu)
   - Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
   - Trastuzumab emtansine (Kadcyla)
   - Any other active systemic anti-cancer therapy
   - Pembrolizumab subcutaneous injection

2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)			

Pertuzumab (Perjeta) + Trastuzumab (Herceptin)			
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel			
Trastuzumab deruxtecan (Enhertu)			
Trastuzumab emtansine (Kadcyla)			
Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)			
Abemaciclib + Fulvestrant			
Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)			
Ribociclib + Fulvestrant			
Capecitabine as a single agent			
Carboplatin + Paclitaxel			
Carboplatin + Paclitaxel + Pembrolizumab			

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients, due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of patients that have been treated for breast cancer (any stage), with the listed Systemic Anti-Cancer Therapies (SACTs), during the period 1 July to 30 September 2026.

SACT	Number
Abemaciclib + Aromatase Inhibitor	28
Abemaciclib + Fulvestrant	0
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel	0
Atezolizumab	0
Capivasertib	*
Capecitabine as a single agent	26
Carboplatin + Paclitaxel	*
Elacestrant	*
Eribulin as a single agent or in combination	*
Everolimus + Exemestane	*
Fulvestrant as a single agent	29
Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	0

Palbociclib + Fulvestrant	11
Parp Inhibitors (Olaparib/Talazoparib)	*
Pembrolizumab Monotherapy	18
Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	0
Carboplatin + Paclitaxel + Pembrolizumab	0
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	0
Phesgo (Pertuzumab + Trastuzumab in a single injection)	45
Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	72
Ribociclib + Fulvestrant	8
Sacituzumab Govitecan	*
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	58
Trastuzumab deruxtecan (Enhertu)	11
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	39
Trastuzumab emtansine (Kadcyla)	14
Any other active systemic anti-cancer therapy	251
Pembrolizumab subcutaneous injection	10

2. The UHB provides within the table overleaf, the number of patients treated with the listed SACTs for breast cancer, by stage, during the period 1 July to 30 September 2026.

SACT	Early	Metastatic	Total
Phesgo (Pertuzumab + Trastuzumab in a single injection)	27	*	45
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	0	0	0
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	24	7	39
Trastuzumab deruxtecan (Enhertu)	0	*	11
Trastuzumab emtansine (Kadcyla)	0	*	14
Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	25	*	28
Abemaciclib + Fulvestrant	0	0	0
Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	45	*	72
Ribociclib + Fulvestrant	0	0	8
Capecitabine as a single agent	5	*	26
Carboplatin + Paclitaxel	0	0	*
Carboplatin + Paclitaxel + Pembrolizumab	0	0	0